Potassium-Sparing Diuretics Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Potassium-Sparing Diuretics. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Potassium-Sparing Diuretics Indian Medical PG Question 1: Severe hyperkalemia is seen in combination with:
- A. Amiloride and Furosemide
- B. Lisinopril and Furosemide
- C. Losartan and amiloride (Correct Answer)
- D. Propranolol and verapamil
Potassium-Sparing Diuretics Explanation: ***Losartan and amiloride*** - **Losartan** is an **angiotensin receptor blocker (ARB)**, often leading to **hyperkalemia** by inhibiting aldosterone secretion. - **Amiloride** is a **potassium-sparing diuretic**, directly interfering with sodium reabsorption and potassium excretion in the **collecting duct**. The combination of Na⁺-channel inhibitors like amiloride with angiotensin-converting enzyme inhibitors (or ARBs) carries a risk of life-threatening hyperkalemia [1].*Amiloride and Furosemide* - **Furosemide** is a **loop diuretic** that causes **potassium wasting**, thus counteracting the potassium-sparing effect of amiloride [2]. - Combining these two drugs typically results in a **neutral or mildly hypokalemic effect**, not severe hyperkalemia.*Lisinopril and furosemide* - **Lisinopril** is an **ACE inhibitor** that causes **hyperkalemia** by reducing aldosterone levels. - However, **furosemide** induces **hypokalemia**, significantly mitigating the hyperkalemic potential of lisinopril [2].*Propranolol and verapamil* - **Propranolol** (a beta-blocker) and **verapamil** (a calcium channel blocker) primarily affect heart rate and contractility, and blood pressure. - Neither of these drugs is directly associated with significant alterations in **potassium levels** to cause severe hyperkalemia.
Potassium-Sparing Diuretics Indian Medical PG Question 2: Potassium-sparing diuretics act at the level of
- A. Carbonic anhydrase
- B. Aldosterone receptor (Correct Answer)
- C. NaCl symporter
- D. Na-K pump
Potassium-Sparing Diuretics Explanation: ***Aldosterone receptor***
- **Potassium-sparing diuretics** include two main classes:
1. **Aldosterone receptor antagonists** (e.g., **spironolactone**, **eplerenone**) that act on **aldosterone receptors** in the collecting tubules
2. **ENaC blockers** (e.g., **amiloride**, **triamterene**) that directly block **epithelial sodium channels (ENaC)** in the collecting duct
- Both mechanisms reduce **sodium reabsorption** and **potassium secretion** in the **collecting tubule**, leading to retained potassium.
- The aldosterone receptor is the most commonly tested site for this drug class.
*Carbonic anhydrase*
- **Carbonic anhydrase inhibitors** (e.g., **acetazolamide**) act primarily in the **proximal convoluted tubule**.
- They inhibit **bicarbonate reabsorption**, leading to diuresis and metabolic acidosis, and are not considered potassium-sparing.
*NaCl symporter*
- **Thiazide diuretics** act on the **NaCl symporter (NCC)** in the **distal convoluted tubule**.
- They inhibit sodium and chloride reabsorption but do not spare potassium; chronic use can lead to **hypokalemia**.
*Na-K pump*
- The **Na-K pump** (Na+/K+-ATPase) is found in many cells and maintains ion gradients, but it is not the primary target of potassium-sparing diuretics.
- While involved in renal transport, diuretics targeting this pump have different primary mechanisms and therapeutic uses.
Potassium-Sparing Diuretics Indian Medical PG Question 3: Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?
- A. Carvedilol
- B. Spironolactone (Correct Answer)
- C. Abiraterone
- D. Sacubitril/Valsartan
Potassium-Sparing Diuretics Explanation: ***Spironolactone***
- **Spironolactone** is a **potassium-sparing diuretic** that acts as a **competitive antagonist of aldosterone** receptors, primarily in the collecting ducts of the kidneys.
- This action leads to increased excretion of sodium and water, and retention of potassium, which is beneficial in **heart failure** by reducing fluid overload and mitigating the detrimental effects of aldosterone on cardiac remodeling.
*Carvedilol*
- **Carvedilol** is a **beta-blocker** with additional **alpha-1 blocking** properties, commonly used in heart failure to reduce heart rate, blood pressure, and myocardial oxygen demand.
- It does not possess significant aldosterone antagonistic properties.
*Sacubitril/Valsartan*
- **Sacubitril/Valsartan** is an **angiotensin receptor-neprilysin inhibitor (ARNI)**. Valsartan is an **angiotensin receptor blocker (ARB)**, and sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides.
- While it modulates the **renin-angiotensin-aldosterone system (RAAS)** and is highly effective in heart failure, it does not directly antagonize aldosterone receptors.
*Abiraterone*
- **Abiraterone** is an **androgen-biosynthesis inhibitor** used in the treatment of **prostate cancer**.
- Its primary mechanism involves inhibiting **CYP17**, an enzyme critical for androgen production, and it has no role in the management of heart failure or aldosterone antagonism.
Potassium-Sparing Diuretics Indian Medical PG Question 4: Which one of the following is not a clinical use of spironolactone?
- A. Pulmonary edema (Correct Answer)
- B. Congestive heart failure
- C. Hypertension
- D. To counteract hypokalemia due to thiazide diuretics
Potassium-Sparing Diuretics Explanation: ***Pulmonary edema***
- While spironolactone is a **diuretic**, its onset of action is relatively slow (days to weeks), making it unsuitable for the acute management of **pulmonary edema**, which requires rapid fluid removal.
- For acute pulmonary edema, fast-acting loop diuretics like **furosemide** are preferred due to their potent and rapid diuresis.
*Congestive heart failure*
- Spironolactone is a **potassium-sparing diuretic** and an **aldosterone antagonist**, which improves outcomes in **congestive heart failure** by reducing fluid retention, myocardial fibrosis, and sympathetic activation.
- It specifically helps in preventing **cardiac remodeling** and has been shown to reduce mortality in patients with heart failure.
*Hypertension*
- Spironolactone is used as an **adjunctive treatment for hypertension**, particularly in cases of **resistant hypertension** or when there is evidence of primary hyperaldosteronism.
- It helps lower **blood pressure** by blocking aldosterone's effects, leading to increased sodium and water excretion.
*To counteract hypokalemia due to thiazide diuretics*
- As a **potassium-sparing diuretic**, spironolactone directly counteracts the **hypokalemia** (low potassium) that can be induced by other diuretics, such as **thiazide diuretics** and **loop diuretics**.
- Its mechanism involves blocking **aldosterone receptors** in the collecting duct, reducing potassium secretion and sodium reabsorption.
Potassium-Sparing Diuretics Indian Medical PG Question 5: Which diuretic is known to cause the maximum potassium loss?
- A. Spironolactone
- B. Furosemide (Correct Answer)
- C. Thiazide diuretics
- D. Acetazolamide
Potassium-Sparing Diuretics Explanation: ***Furosemide***
- Furosemide is a **loop diuretic** that inhibits the Na-K-2Cl cotransporter in the **thick ascending limb of the loop of Henle**, leading to significant excretion of sodium, chloride, potassium, and water.
- Its potent diuresis and impact on potassium reabsorption result in a **high risk of hypokalemia**.
*Thiazide*
- Thiazide diuretics inhibit the **Na-Cl cotransporter** in the **distal convoluted tubule**, causing moderate sodium and water excretion, and some potassium loss.
- While they can cause hypokalemia, their effect on potassium excretion is generally **less pronounced than loop diuretics**.
*Acetazolamide*
- Acetazolamide is a **carbonic anhydrase inhibitor** that acts primarily in the **proximal tubule**, inhibiting bicarbonate reabsorption and leading to increased excretion of bicarbonate, sodium, potassium, and water.
- The potassium loss is due to increased delivery of sodium to the collecting duct, leading to enhanced potassium secretion, but it is typically **less severe than with loop diuretics**.
*Spironolactone*
- Spironolactone is a **potassium-sparing diuretic** that acts as an **aldosterone antagonist** in the collecting duct, inhibiting sodium reabsorption and potassium secretion.
- Instead of causing potassium loss, spironolactone actually **conserves potassium** and can lead to hyperkalemia.
Potassium-Sparing Diuretics Indian Medical PG Question 6: All of the following diuretics increase K+ excretion EXCEPT:
- A. Acetazolamide
- B. Triamterene (Correct Answer)
- C. Thiazide
- D. Furosemide
Potassium-Sparing Diuretics Explanation: ***Triamterene***
- **Triamterene** is a **potassium-sparing diuretic** that blocks epithelial sodium channels (ENaC) in the collecting duct, thereby reducing sodium reabsorption and potassium secretion.
- Unlike most other diuretics, it causes **decreased K+ excretion** and can lead to hyperkalemia.
*Acetazolamide*
- **Acetazolamide** is a **carbonic anhydrase inhibitor** that acts in the proximal tubule, inhibiting bicarbonate reabsorption.
- This leads to increased delivery of sodium and bicarbonate to the collecting duct, which enhances **potassium secretion** and increases K+ excretion.
*Thiazide*
- **Thiazide diuretics** (e.g., hydrochlorothiazide) act by inhibiting the Na+/Cl- cotransporter in the **distal convoluted tubule**.
- This increases the delivery of sodium to the collecting duct, which stimulates the exchange of sodium for **potassium**, leading to increased K+ excretion and hypokalemia.
*Furosemide*
- **Furosemide** is a **loop diuretic** that inhibits the Na+/K+/2Cl- cotransporter in the **thick ascending limb of the loop of Henle**.
- This prevents the reabsorption of these ions, leading to increased delivery of sodium to the collecting duct, which promotes **potassium secretion** and increased K+ excretion.
Potassium-Sparing Diuretics Indian Medical PG Question 7: The site of action of the loop diuretic furosemide is:
- A. Distal convoluted tubule
- B. Descending limb of loop of Henle
- C. Proximal convoluted tubule
- D. Thick ascending limb of loop of Henle (Correct Answer)
Potassium-Sparing Diuretics Explanation: ***Thick ascending limb of loop of Henle***
- Furosemide, a **loop diuretic**, acts by inhibiting the **Na+-K+-2Cl- cotransporter (NKCC2)** in the luminal membrane of the epithelial cells in the thick ascending limb.
- This inhibition prevents the reabsorption of these ions, leading to increased excretion of **sodium**, **potassium**, **chloride**, and water.
*Distal convoluted tubule*
- This is the primary site of action for **thiazide diuretics**, which inhibit the **Na+-Cl- cotransporter**.
- While some water reabsorption occurs here, it is not the main target for loop diuretics like furosemide.
*Descending limb of loop of Henle*
- This segment is primarily permeable to **water** due to aquaporins but impermeable to solutes, allowing for passive water reabsorption.
- No significant transport mechanisms are directly targeted by furosemide here.
*Proximal convoluted tubule*
- The proximal tubule is where the majority of filtered **sodium**, **water**, and other solutes are reabsorbed.
- **Carbonic anhydrase inhibitors** (e.g., acetazolamide) primarily act here.
Potassium-Sparing Diuretics Indian Medical PG Question 8: All of the following drugs are known to worsen hyperkalemia except
- A. Furosemide (Correct Answer)
- B. ACE inhibitors
- C. Amiloride
- D. Spironolactone
Potassium-Sparing Diuretics Explanation: ***Furosemide***
- **Furosemide** is a loop diuretic that acts on the **thick ascending limb of the loop of Henle**, inhibiting the reabsorption of sodium, chloride, and potassium.
- This action leads to increased excretion of potassium in the urine, thus **preventing hyperkalemia** and often causing hypokalemia.
*ACE inhibitors*
- **ACE inhibitors** block the production of angiotensin II, leading to decreased aldosterone secretion.
- Reduced aldosterone levels decrease potassium excretion in the renal tubules, which can **worsen hyperkalemia**.
*Amiloride*
- **Amiloride** is a potassium-sparing diuretic that blocks sodium channels in the collecting duct.
- This action reduces potassium secretion, making it a drug that can **worsen hyperkalemia**.
*Spironolactone*
- **Spironolactone** is an aldosterone antagonist that also acts as a potassium-sparing diuretic.
- By blocking aldosterone's effects, it **decreases potassium excretion** in the renal tubules and can therefore worsen hyperkalemia.
Potassium-Sparing Diuretics Indian Medical PG Question 9: Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?
- A. Spironolactone (Correct Answer)
- B. Amiloride
- C. Triamterene
- D. Eplerenone
Potassium-Sparing Diuretics Explanation: ***Spironolactone***
- **Spironolactone** was the first potassium-sparing diuretic shown to reduce **cardiac mortality** in patients with **chronic heart failure** in the **RALES trial** (Randomized Aldactone Evaluation Study).
- Its beneficial effects in heart failure are primarily attributed to its **aldosterone receptor antagonist** properties, which counteract the harmful effects of aldosterone on the myocardium and vasculature, rather than just its diuretic effect.
*Amiloride*
- **Amiloride** is a potassium-sparing diuretic that works by directly inhibiting **epithelial sodium channels (ENaC)** in the collecting duct.
- While it helps in potassium conservation, it has not been shown to significantly reduce cardiac mortality in chronic heart failure patients in clinical trials.
*Triamterene*
- **Triamterene** is another potassium-sparing diuretic that also directly inhibits **ENaC** in the collecting duct, similar to amiloride.
- Like amiloride, it is used to prevent hypokalemia but lacks evidence for significant **cardiac mortality reduction** in chronic heart failure.
*Eplerenone*
- **Eplerenone** is a selective **aldosterone receptor antagonist**, similar to spironolactone, with fewer hormonal side effects.
- While it has been shown to reduce **cardiac mortality** in chronic heart failure (e.g., in the EMPHASIS-HF trial), it was introduced later than spironolactone and was not the *first* to demonstrate this benefit.
Potassium-Sparing Diuretics Indian Medical PG Question 10: Which electrolyte shows the most significant increase in urinary excretion within 24 hours of initiating thiazide diuretic therapy for hypertension?
- A. Sodium (Correct Answer)
- B. Potassium
- C. Magnesium
- D. Calcium
Potassium-Sparing Diuretics Explanation: ***Sodium***
- Thiazide diuretics primarily act on the **distal convoluted tubule** by inhibiting the **Na+/Cl- cotransporter**, leading to increased excretion of **sodium** and water [1].
- The initial and most significant pharmacological effect of thiazides is to promote **natriuresis**, removing excess sodium from the body [2].
- Within **24 hours**, sodium excretion shows the most pronounced increase, which is the primary mechanism for blood pressure reduction [2].
*Potassium*
- While thiazides do cause **potassium excretion**, this effect is less significant than sodium excretion initially and is partly due to increased flow to the collecting duct and elevated aldosterone levels [2].
- Hypokalemia is a known side effect of long-term thiazide use, but the **immediate increase in urinary sodium** is more pronounced.
*Magnesium*
- Thiazide diuretics are known to cause **increased urinary excretion of magnesium**, which can lead to hypomagnesemia with chronic use [3].
- However, the initial increase in magnesium excretion is generally **less pronounced** compared to sodium excretion within the first 24 hours of therapy.
*Calcium*
- Uniquely among diuretics, thiazides **decrease** urinary calcium excretion, promoting calcium retention and reabsorption in the distal tubule [1], [3].
- This is why thiazides are sometimes used therapeutically in **hypercalciuric nephrolithiasis** and can cause hypercalcemia as a side effect.
- Calcium excretion is **reduced**, not increased, making this the opposite of the correct answer.
More Potassium-Sparing Diuretics Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
